What Fueled The Previous Growth In The Tremfya Market?
The tremfya market has seen considerable growth due to a variety of factors.
• In recent years, the market size for tremfya has experienced a XX (HCAGR) growth. The market is projected to expand from $XX million in 2024 to $XX million in 2025, yielding a compound annual growth rate (CAGR) of XX%.
The historical growth has been driven by the escalating occurrence of psoriasis and psoriatic arthritis, an intensified focus on targeted treatments, increased healthcare funding, a surge in the number of specialty clinics, and a heightened uptake of biologics in the fields of dermatology and rheumatology.
What Can Be Expected from the Tremfya Market?
The tremfya market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are set for the tremfya market size to witness a XX (FCAGR) increase in the upcoming years. The estimated growth points to a figure of $XX million by 2029, progressing at a compound annual growth rate (CAGR) of XX%.
The rise during the prediction period can be linked to enhancements in the healthcare infrastructure, a growing preference for point-of-care testing, escalated investments in healthcare-related research, and a heightened emphasis on precision medicine. Noteworthy trends over the forecast period encompass progress in treatment methods, personalized medicine practices, the incorporation of technology in patient observation, the implementation of artificial intelligence (AI), and advancements in injection device technology.
What Are the Critical Driver Fuelling The Tremfya Market's Growth?
The escalating occurrence of autoimmune diseases is predicted to fuel the expansion of the tremfya market. Autoimmune diseases are conditions where the immune system erroneously fights against its cells, tissues, or organs, seeing them as dangerous aliens. The escalating occurrence of these diseases is attributed to genetic predisposition, environmental factors, alterations in lifestyle, heightened awareness, and enhanced diagnostic capabilities. Tremfya, an antibody that targets interleukin-23 (IL-23), is instrumental in managing autoimmune diseases. It modulates the hyperactive response of the immune system while reducing inflammation and mitigating symptoms in conditions like psoriasis and psoriatic arthritis. For instance, in June 2024, as per a report by the Australian Institute of Health and Welfare, a governmental organization based in Australia, it was reported that in 2022, rheumatoid arthritis led to 10,000 hospitalizations. This marked a 25% rise from 8,000 the previous year, with a hospitalization rate of 39 per 100,000 people. Hence, the escalating occurrence of autoimmune diseases is pushing the growth of the tremfya market.
How Is The Tremfya Market segmented?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA
2) By Formulation: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By End User: Adult Patients, Geriatric Patients
Pre-Book The Tremfya Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Tremfya Market?
An important development in the Tremfya market is the acquisition of regulatory approvals to extend its treatment applications, including for moderate-to-severe Crohn's disease, enhancing its patient reach and market potential. Regulatory approvals are formal permissions granted by bodies such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA), allowing the marketing of a drug for specific purposes, provided its safety, efficacy, and quality have been proven. For example, Johnson & Johnson, a pharmaceutical company based in the US, secured FDA approval for TREMFYA (guselkumab) for treating adults with moderately to severely active ulcerative colitis in September 2024, marking the first approval for a dual-acting interleukin-23 inhibitor for this ailment. The approval was predicated on positive outcomes from the Phase 2b/3 QUASAR study, demonstrating that about 50% of patients achieved clinical remission after 44 weeks of therapy. TREMFYA works by targeting interleukin-23, which aids in regulating the inflammatory response in the colon.
Who Are the Key Players In The Tremfya Market?
Major companies operating in the tremfya market are:
• Johnson & Johnson
What Is The Most Dominant Region In The Tremfya Market?
North America was the largest region in the tremfy market in 2024. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
